Acne & Rosacea

An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris Linda Stein Gold, Sunhil Dhawan, Jonathan Weiss, Zoe Diana Draelos, Herman Ellman, Iain Stuart

Poster PDF S1

Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris L Eichenfield, L Stein Gold, N Silverberg, T Raoof, D Hooper, A Moore, M Zaiac, T Sullivan, L Kircik, E Lain, S Dhawan, T Jones, J Weiss, Z Draelos, H Ellman, T deVries, J Jankicevic, I Stuart

Poster PDF S2

Ex Vivo Assessment of FMX101 & FMX103 Human Skin Permeation and Penetration Russell Elliott, Gary Lawrence, Yohan Hazot, Lenny Margulis, Vassilis Stakias, Iain Stuart

Poster PDF S3

Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris James Q Del Rosso, Corey L Hartman, Caitlin Lewis, Rhonda Schreiber

Poster PDF S4

Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population George Han, April W Armstrong, Seemal R Desai, Eric Guenin

Poster PDF S5

A Randomized, Observer‑Blind, Split‑Face Study to Assess Compatibility of Facial Foundation Makeup with Tretinoin 0.05% Lotion and Skin Texture After Application Neal Bhatia, Leon H Kircik, Ava Shamban, Varsha Bhatt, Radhakrishnan Pillai, Eric Guenin

Poster PDF S6

Acne-Related Quality of Life: Efficacy of a Novel Tretinoin 0.05% Lotion in Male and Female Patients with Moderate-to-Severe Disease Sharleen St. Surin-Lord, William Philip Werschler, Eric Guenin

Poster PDF S7

Acne-Related Quality of Life: Correlation Between Acne Symptom Scores and Other Domains Following Treatment with Tretinoin 0.05% Lotion Heather C Woolery-Lloyd, Julie C Harper, Eric Guenin

Poster PDF S8

Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial Zoe Draelos, Fran Cook-Bolden, Lawrence Green, Eric Guenin, Gina Martin, Radhakrishnan Pillai

Poster PDF S9

DFD 29, a low dose oral minocycline, shows significant improvement in quality of life in subjects with papulopustular rosacea Linda Stein Gold, Joshua Zeichner, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi

Poster PDF S10

DFD-29, a low dose oral minocycline, demonstrates superior efficacy as compared to placebo and Oraycea ® Capsules (doxycycline HCl) in subjects with papulopustular rosacea Athanasios Tsianakas, Neal Bhatia, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi

Poster PDF S11

Psoriasis

An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study D Thaci, K Papp, K Gordon, A Morita, M Gooderham, P Foley, E Alemano, R Kisa, Y Elbez, H Ren, S Banerjee

Poster PDF S12

Lack of ECG effects of BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: results from a thorough QT study in healthy subjects IG Girgis, A Chimalakonda, JP Jones III, R Dockens, D Marchisin, R Darbenzio, S Singhal, J Throup, S Banerjee

Poster PDF S13

Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial K Gordon, K Papp, M Gooderman, D Thaci, P Foley, A Morita, S Kundu, R Kisa, A Napoli, S Banerjee

Poster PDF S14

Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study Mark Lebwohl, James Del Rosso, Chih-ho Hong, Anna M Tallman, Leon Kircik

Poster PDF S15

Secondary Efficacy Outcomes from a Phase 2b, Randomized Dose-Finding Study of Tapinarof Cream for the Treatment of Plaque Psoriasis Linda Stein Gold, Neal Bhatia, Anna M Tallman, David Rubenstein

Poster PDF S16

Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial C.E.M. Griffiths, K.A. Papp, M Song, M Miller, Y You, Y-K Shen, C Han, A Blauvelt

Poster PDF S17

A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis. Adelaide A Herbert, Debbie Glaab, Rhonda Schreiber

Poster PDF S18

Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis Francisco Kerdel, Christina Don, Renata Block, Caitlin Lewis, Rhonda Schreiber

Poster PDF S19

Patients With Psoriasis Treated With Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver Inflammation in Individuals With Potential Indicators of Early Nonalcoholic Fatty Liver Disease Ronald Prussick, Mark Lebwohl, Nadege Gunn, Susan Harris, Jason Vittitow, Abby Jacobson, Robert J Israel

Poster PDF S20

Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies Alice Gottlieb, Alan Menter, Paul Yamauchi, George Han, Radhakrishnan Pillai, Tina Lin, Abby Jacobson

Poster PDF S21

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Whose Disease Did Not Respond to Prior Biologics Mark Lebwohl, Lawrence Green, Miriam Bettencourt, Scott Fretzin, Abby Jacobson

Poster PDF S22

Maintenance and Improvement of Skin Clearance Response With Brodalumab Among Patients With Moderate-to-Severe Psoriasis Neal D Bhatia, Seemal R Desai, Craig Teller, Abby Jacobson

Poster PDF S23

Importance of Complete Skin Clearance on Quality of Life: Analysis of Three Phase 3 Studies of Brodalumab April Armstrong, Andrew Blauvelt, Scott Drew, Roger Ho, Abby Jacobson

Poster PDF S24

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies Benjamin Ehst, George Han, Scott Guenthner, Kimberly Eads, Abby Jacobson

Poster PDF S25

Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab Mark Lebwohl, Andrew Blauvelt, Alan Menter, Kim Papp, Abby Jacobson

Poster PDF S26

Optimized Formulation for Topical Application of a Fixed Combination Halobetasol/Tazarotene Lotion Using Polymeric Emulsion Technology Emil A Tanghetti, Linda Stein Gold, James Q Del Rosso, Stefan Weiss, Tina Lin, Arturo Angel, Radhakrishnan Pillai

Poster PDF S27

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials Andrew F Alexis, Paul S Yamauchi, Tina Lin, Gina Martin

Poster PDF S28

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials Mark G Lebwohl, Jeffrey L Sugarman, Linda Stein Gold, Tina Lin, Gina Martin

Poster PDF S29

Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast) Brad Glick, Edward Lain, Tina Lin, Robert Israel

Poster PDF S30

Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion Lina Stein Gold, Mark G Lebwohl, Neal Bhatia, Tina Lin, Radhakrishnan Pillai

Poster PDF S31

Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities Neal Bhatia, Tracey C Vlahovic, Lawrence Green, Gina Martin, Tina Lin

Poster PDF S32

PPC 06 ( Tepilamide Fumarate), a novel fumaric acid ester, is efficacious in treating plaque psoriasis: Results from a phase 2b randomized controlled trial Mark Lebwohl, Leon Kircik, Kristian Reich, Sugar Munjal, Srinivas Shenoy, Ulrich Mrowietz

Poster PDF S33

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study Andrew Blauvelt, Kim A Papp, Joseph F Merola, Alice B Gottlieb, Nancy Cross, Cindy Madden, Luke Peterson, Christopher Cioffi, Christopher EM Griffiths

Poster PDF S34

Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study Kim A Papp, Joseph F Merola, Alice B Gottlieb, Christopher EM Griffiths, Kristina K Harris, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt

Poster PDF S35

Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) K Gordon, R.B. Warren, A.B. Gottlieb, A Blauvelt, D Thaci, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich

Poster PDF S36

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) K Gordon, R.B. Warren, A.B. Gottlieb, A. Blauvelt, D Thaci, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich

Poster PDF S37

Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials A.B. Gottlieb, D Thaci, C Leonardi, Y Poulin, S Kavanagh, M Boehnlein, K Reich

Poster PDF S38

Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) A Blauvelt, B Strober, R Langley, S Kavanagh, C Arendt, M Boehnlein, M Lebwohl, K Reich

Poster PDF S39

Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2 P van de Kerkhof, A Pinter, M Boehnlein, S Kavanagh, J.J. Crowley

Poster PDF S40

Eczema & Xerosis

Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study E Guttman-Yassky, A Blauvelt, L.F. Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson

Poster PDF S41

Atopic dermatitis disease biomarkers strongly correlate with IL-13 levels, are regulated by IL-13, and are modulated by tralokinumab in vitro Stephan Weidinger, Maxim A.X. Tollenaere, Katharina Drerup, Thomas Litman, Hanne Norsgaard

Poster PDF S42

The Low Prevalence of Allergic Contact Dermatitis Using a Petrolatum Ointment Containing Lanolin Alcohol Z Draelos, L Kircik, D Rigel

Poster PDF S43

A Comparison of Efficacy among Therapeutic Moisturizing Creams CE Arrowitz, LI Jiang, PD Hino, MJ Babcock, TM Weber

Poster PDF S44

A 14 Day, Single Blind, Controlled Study to Assess the Qualitative Improvement in Skin Moisturization and Desquamation of 15% Lactic Acid Moisturizer with Ceramides (LAMC) Treatment in Healthy Female Subjects Zoe Diane Draelos, Steven B Hall, Carey Munsick

Poster PDF S45

Skin Cancer

Safety of Large Field (>20cm2) Photodynamic Therapy Using 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel Comparing Blue to Red Light Illumination Angela Yen Moore, Stephen Moore

Poster PDF S46

Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial T Dirschka, M Ulrich, U Reinhold, R Dominicus, R Aschoff, R.M. Szeimies

Poster PDF S47

A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA and narrowband red light in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT) V Laquer, S Bruce, T Schlesinger, N Zeitouni, A Torres, J Cohen, J Tu, W Hanke, M Goldman, D Ozog, O Markowitz, M Gold, M Nestor, B Berman, G Munavalli, D Pariser

Poster PDF S48

Follow-up results of a randomized, double-blind, phase III, multi-center study to evaluate the safety and efficacy of BF-200 ALA versus placebo in field-directed treatment of mild to moderate AK with photodynamic therapy when using narrowband red light U Reinhold, T Dirschka, R Ostendorf, R Aschoff, C Berking, W Philipp-Dormston, R.M. Szeimies

Poster PDF S49

Multidisciplinary Expert-Driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma Michael R Migden, Todd E Schlesinger, Chrysalyne D Schmults, Scott M Dinehart, Robert L Ferris, Morganna Freeman, Valerie Guild, Shlomo Koyfman, Anna C Pavlick, Gregory T Wolf, Guilherme Rabinowits, Neil Swanson

Poster PDF S50

Recurrence prediction in cutaneous melanoma with 31-gene expression profiling and sentinel lymph node biopsy Graham Litchman, Hilary Caruso, Robert Cook, Darrell Rigel

Poster PDF S51

Findings from a large US registry study to assess the real-world utility of a non-invasive gene expression test designed to rule out primary cutaneous melanoma Brook Brouha, Laura K Ferris, Maral K Skelsey, Gary Peck, Zuxu Yao, Burkhard Jansen

Poster PDF S52

Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandala, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Laurent Mortier, Caroline Robert, Jacob Schachter, Christine-Elke Ortmann, Egbert de Jong, Edward Gasal, Richard Kefford, John M Kirkwood, Georgina V Long

Poster PDF S53

Hyperhidrosis

A Multi-Center, Open-Label Study to Assess Pharmacokinetics (PK), Safety and Tolerability of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, ≥9 to <17 Years of Age, with Axillary Hyperhidrosis Brandon Kirsch, Janet DuBois, Deepak Chadha

Poster PDF S54

Limited Systemic Exposure with Topical Glycopyrronium Tosylate across Multiple Studies in Healthy Volunteers and Patients with Primary Axillary Hyperhidrosis D.M. Pariser, E.L. Lain, R Mamelok, J Drew, D.R. Mould

Poster PDF S55

Dermatopharmacology

Measuring the Predictive Value of Serological Quantification of Cytokines with the Onset of Influenza-Like Signs and Symptoms Induced by Imiquimod 3.75% Cream: Results of a Single Center, Open-Label, Proof of Concept Trial Neal Bhatia

Poster PDF S56

Comparative Pharmacokinetic Profiles of a Novel Low-Dose Micronized-Isotretinoin 32-mg Formulation and Lidose-Isotretinoin 40 mg in Fed and Fasted Conditions: 2 Open-label, Randomized Crossover Studies in Healthy Adult Participants Sumit Madan, Sudershan Kumar, Jeanett Segal

Poster PDF S57